Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Desmin 370 (Opocrin SpA/Alfa Wassermann).

D Mungall1

  • 1Department of Pharmacy, Tallahassee Memorial Health Care, Tallahassee, FL 32308, USA. Thertch@aol.com

Idrugs : the Investigational Drugs Journal
|August 30, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A survey of anesthesiologists' and nurses' attitudes toward the implementation of an Anesthesia Information Management System on a labor and delivery floor.

International journal of obstetric anesthesia·2008
Same author

Developing and testing a system to improve the quality of heparin anticoagulation in patients with acute cardiac syndromes.

The American journal of cardiology·1998
Same author

Activated partial thromboplastin time vs heparin concentration.

Archives of internal medicine·1998
Same author

Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steady-state intravenous heparin requirements.

Archives of internal medicine·1997
Same author

Changes in plasma warfarin levels and variations in steady-state prothrombin times.

Clinical pharmacology and therapeutics·1995
Same author

Comment: Heparin infusion rates.

The Annals of pharmacotherapy·1994
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Desmin 370 is an antithrombotic agent in phase III trials for deep vein thrombosis and potentially pulmonary embolism. It works by inhibiting thrombin generation and enhancing fibrinolysis.

Area of Science:

  • Pharmacology
  • Vascular Medicine
  • Drug Development

Background:

  • Deep vein thrombosis (DVT) and pulmonary embolism (PE) are significant causes of morbidity and mortality.
  • Antithrombotic agents are crucial for managing and preventing these conditions.
  • Current treatments have limitations, necessitating the development of novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy and safety of Desmin 370, an investigational antithrombotic agent.
  • To explore the potential of Desmin 370 in treating deep vein thrombosis (DVT) and pulmonary embolism (PE).

Main Methods:

  • Phase III clinical trials are underway to assess Desmin 370.
  • The study involves evaluating Desmin 370's mechanism of action, including thrombin generation inhibition, heparin cofactor II potentiation, and local fibrinolytic effects.

Related Experiment Videos

Main Results:

  • Desmin 370 is currently in phase III clinical trials, indicating promising preliminary data.
  • The agent demonstrates antithrombotic effects through multiple mechanisms.

Conclusions:

  • Desmin 370 shows potential as a novel therapeutic agent for deep vein thrombosis and pulmonary embolism.
  • Further clinical research is ongoing to confirm its efficacy and safety profile.